Last updated: September 9, 2026
Loratadine plus pseudoephedrine sulfate is a mature, largely genericized oral decongestant-antihistamine combination sold primarily as Claritin-D and store-brand equivalents. The active ingredients have no meaningful remaining composition-of-matter exclusivity in the United States. Commercial performance depends on brand recognition, retailer distribution, seasonal allergy demand, formulation differentiation, and pseudoephedrine purchasing restrictions rather than patent protection.
Claritin-D remains commercially relevant, but its revenue trajectory is structurally constrained by low-cost generic competition, limited product innovation, and the mature status of the allergy and cold-drug categories. Bayer does not publicly report Claritin-D revenue as a separate line item.
What products contain loratadine and pseudoephedrine sulfate?
The combination is marketed in extended-release oral tablets, principally in two strengths:
| Product type |
Loratadine |
Pseudoephedrine sulfate |
Typical dosing |
| 12-hour tablet |
5 mg |
120 mg |
One tablet every 12 hours |
| 24-hour tablet |
10 mg |
240 mg |
One tablet every 24 hours |
The best-known branded product is Claritin-D, marketed by Bayer Consumer Health in the United States. Generic equivalents are sold by multiple manufacturers and retailers under store brands such as loratadine-pseudoephedrine or loratadine and pseudoephedrine extended-release tablets.
The product combines loratadine, a second-generation H1 antihistamine, with pseudoephedrine, a systemic nasal decongestant. Loratadine addresses histamine-mediated allergy symptoms. Pseudoephedrine reduces nasal congestion through vasoconstriction.
The combination is used for allergic rhinitis with nasal congestion. It is not interchangeable with plain loratadine products because pseudoephedrine adds cardiovascular, central nervous system, and regulatory restrictions.
What is the FDA regulatory status of loratadine-pseudoephedrine?
Loratadine and pseudoephedrine products are nonprescription drugs in the United States. Plain loratadine was switched from prescription to OTC status in 2002. Combination products are regulated under the FDA OTC framework and through product-specific approved applications and labeling requirements.[1]
Pseudoephedrine remains subject to the Combat Methamphetamine Epidemic Act of 2005. Retail sales require purchase-quantity controls, transaction records, identification requirements, and, in many states, behind-the-counter placement.[2]
Key regulatory characteristics include:
- OTC availability rather than prescription-only distribution.
- Retail restrictions based on pseudoephedrine content.
- Purchase limits of 3.6 grams per day and 9 grams over a 30-day period under federal law.
- State-level restrictions that can be stricter than federal requirements.
- Expanded scrutiny of abuse-deterrence, inventory control, and electronic sales monitoring.
- No biologic or biosimilar pathway because the products are small-molecule drugs.
The FDA’s OTC Monograph Drug Facts database and Orange Book should be distinguished. The Orange Book primarily lists approved prescription and certain approved nonprescription applications. The existence of an OTC brand does not mean that all related commercial products have a conventional Orange Book patent listing.
What patents protect Claritin-D and generic loratadine-pseudoephedrine?
The core patent estate is expired or commercially ineffective against ordinary generic competition.
| IP category |
Current commercial position |
| Loratadine composition patents |
Expired |
| Pseudoephedrine composition rights |
Expired and historically unavailable as a durable branded barrier |
| Basic allergy treatment claims |
Expired or vulnerable to prior-art challenges |
| Extended-release combination technology |
Legacy rights are generally expired or narrow |
| Trademark rights |
Claritin and Claritin-D remain valuable brand assets |
| Trade dress and packaging |
May support brand enforcement but does not block therapeutic substitution |
| Manufacturing know-how |
Can affect cost and supply reliability but generally does not prevent generic entry |
The original loratadine patent family dates from the 1980s. The principal U.S. composition-of-matter protection expired around the early 2000s, subject to applicable patent-term adjustments and extensions. The later commercial opportunity was protected more heavily through regulatory exclusivity, brand marketing, formulation positioning, and distribution than through an enduring patent moat.
What formulation patents cover loratadine-pseudoephedrine products?
Extended-release products can involve claims covering:
- Bilayer or multilayer tablet structures.
- Immediate-release loratadine combined with extended-release pseudoephedrine.
- Controlled-release matrices.
- Coated particles or pellets.
- Release-rate profiles.
- Tablet manufacturing processes.
- Stability and moisture-control techniques.
These claims may have delayed or narrowed generic competition at particular points in the product lifecycle. They do not generally create a current broad barrier because the combination has been marketed for decades and multiple generic products are available.
A generic manufacturer can also design around expired or narrow formulation claims by using a different matrix, coating system, particle size, excipient profile, or manufacturing process, provided the product meets FDA performance and bioequivalence requirements.
When does loratadine-pseudoephedrine lose exclusivity?
The combination lost practical exclusivity years ago. The relevant timeline is:
| Date or period |
Event |
| 1980s |
Loratadine composition patents filed and issued |
| 1990s |
Loratadine products commercialized under Claritin |
| Early 2000s |
Core loratadine patent protection expired |
| 2002 |
Loratadine moved from prescription to OTC distribution |
| 2005 |
Federal pseudoephedrine controls expanded under the Combat Methamphetamine Epidemic Act |
| 2000s onward |
Generic loratadine-pseudoephedrine products entered the U.S. market |
| Current period |
Competition is primarily brand-versus-generic and retailer-versus-retailer |
Patent expiry dates can vary by jurisdiction, patent family, patent-term adjustment, pediatric exclusivity, and the specific product claim. Those variables do not change the commercial conclusion: the basic combination is off-patent.
What is the Orange Book status of Claritin-D?
Claritin-D does not have the same Orange Book-driven market structure as a currently patent-protected prescription drug.
The Orange Book is relevant when an approved application contains listed patents and a generic applicant must submit Paragraph IV certifications. For mature OTC loratadine-pseudoephedrine products, the principal competitive issues are usually:
- OTC application and monograph compliance.
- Product quality and bioequivalence.
- Extended-release performance.
- Labeling.
- Pseudoephedrine retail controls.
- Manufacturing capacity and supply continuity.
A current, commercially material Orange Book patent barrier for Claritin-D is not the primary driver of market access. Brand owners may still hold trademarks, regulatory know-how, formulation rights, or patents covering narrow manufacturing features.
Are there Paragraph IV challenges to Claritin-D?
Paragraph IV litigation is not the principal competitive mechanism for this product category today. Paragraph IV certifications apply to abbreviated new drug applications referencing listed patents in an approved application. Because Claritin-D is a mature OTC product with expired core exclusivity and broad generic availability, the commercial market is not dependent on an unresolved Paragraph IV dispute.
Potential patent disputes could still arise over a specific extended-release formulation or a newly approved product, but those disputes would concern narrow claim scope rather than the loratadine-pseudoephedrine combination as a whole.
Which companies compete with Claritin-D?
Competition is fragmented across branded, authorized-generic, store-brand, and independent generic channels.
Brand competitors
Relevant adjacent products include:
- Allegra-D, containing fexofenadine and pseudoephedrine.
- Zyrtec-D, containing cetirizine and pseudoephedrine.
- Sudafed products containing pseudoephedrine without an antihistamine.
- Claritin tablets containing loratadine without pseudoephedrine.
- Nasal corticosteroids, including fluticasone products, for congestion and allergic rhinitis.
Generic and private-label competitors
Retailers and generic suppliers compete through:
- Lower price.
- Pharmacy and mass-retail placement.
- Online ordering where legally permitted.
- 12-hour and 24-hour formats.
- Retailer-specific packaging.
- Supply availability during seasonal demand peaks.
The combination also competes indirectly with intranasal corticosteroids and newer antihistamines. These alternatives can reduce demand for systemic decongestant combinations among consumers with persistent congestion, hypertension concerns, insomnia, or contraindications to pseudoephedrine.
How strong is the patent estate for loratadine-pseudoephedrine?
The patent estate is weak as a current exclusivity asset and moderate only as a historical product-development asset.
| Factor |
Assessment |
| Composition-of-matter protection |
None of practical current value |
| Formulation protection |
Mostly expired, narrow, or design-around capable |
| Regulatory exclusivity |
Expired |
| Trademark strength |
High for Claritin |
| Manufacturing barrier |
Low to moderate |
| Retail access barrier |
Moderate because of pseudoephedrine controls |
| Generic substitution risk |
High |
| Brand pricing power |
Moderate in seasonal periods, low in chronic generic channels |
The main defensible assets are Claritin brand recognition, consumer trust, shelf placement, advertising reach, and supply-chain execution. Those assets support a price premium but do not prevent substitution.
What is the financial trajectory for Claritin-D?
Bayer reports Claritin within its Consumer Health business, but it does not generally disclose standalone revenue, gross margin, or operating profit for Claritin-D. Product-level revenue estimates from market-research providers may differ based on channel coverage, private-label treatment, and whether sales include plain loratadine.
The financial trajectory has four stages:
- Prescription-to-OTC expansion. Loratadine gained broad household use after OTC conversion, expanding volume and lowering access barriers.
- Brand maturation. Claritin became a major allergy brand, supported by advertising and physician-to-consumer marketing.
- Generic erosion. Off-patent competition reduced average selling prices and shifted volume toward store brands.
- Stable mature-category monetization. The brand now depends on seasonal demand, retail execution, product availability, and brand loyalty.
Revenue exposure is concentrated in consumer health rather than prescription specialty pharmaceuticals. The product has low clinical development expense because no new molecular entity is involved. Its profitability is therefore driven by marketing, manufacturing, distribution, retailer negotiations, and portfolio economics.
What factors could improve revenue?
- Severe or prolonged allergy seasons.
- Higher consumer preference for oral combination therapy.
- Stronger pharmacy and mass-retail distribution.
- Temporary generic shortages.
- Premium pricing for 24-hour convenience.
- Cross-selling within the Claritin franchise.
What factors could reduce revenue?
- Store-brand substitution.
- Lower use of pseudoephedrine because of safety concerns.
- Retail access friction caused by purchase controls.
- Consumer migration to intranasal corticosteroids.
- Generic price compression.
- Supply interruptions.
- Public or regulatory pressure on systemic decongestants.
Bayer’s reported Consumer Health results provide the appropriate corporate-level financial reference, but they should not be treated as Claritin-D revenue. Bayer’s annual reports group multiple categories and brands together.[3]
What generic launch risks exist for Claritin-D?
Generic entry risk is already realized rather than prospective. The relevant business risk is continued substitution and price erosion.
A new generic entrant would face:
- FDA product-quality and extended-release requirements.
- Pseudoephedrine procurement and distribution controls.
- Retailer qualification requirements.
- Seasonal inventory timing.
- Established generic and private-label competitors.
- Potential formulation patents of limited scope.
- Pharmacist and consumer preference for known brands.
A launch can still be commercially attractive if a supplier has low manufacturing costs, reliable pseudoephedrine sourcing, retailer contracts, or a differentiated 24-hour format. The market is unlikely to support premium pricing without brand investment or supply scarcity.
What manufacturing and IP barriers affect the market?
Manufacturing barriers are more relevant than patent barriers. Extended-release combination tablets require control of:
- Drug release over the labeled dosing interval.
- Content uniformity across active ingredients.
- Tablet hardness and coating integrity.
- Stability under moisture and temperature stress.
- Dissolution testing.
- Packaging that protects product quality.
- Controlled procurement and documentation for pseudoephedrine.
Pseudoephedrine controls create an operational barrier because manufacturers, distributors, pharmacies, and retailers must maintain transaction records and comply with federal and state limits. These requirements raise compliance costs but do not establish durable exclusivity.
How does Claritin-D compare with Allegra-D and Zyrtec-D?
| Product |
Antihistamine |
Decongestant |
Main commercial advantage |
Main limitation |
| Claritin-D |
Loratadine |
Pseudoephedrine |
Long-established brand and once-daily option |
Generic and private-label pressure |
| Allegra-D |
Fexofenadine |
Pseudoephedrine |
Low-sedation positioning |
Higher complexity and generic competition |
| Zyrtec-D |
Cetirizine |
Pseudoephedrine |
Strong allergy brand recognition |
Cetirizine may cause more sedation in some users |
| Sudafed |
None |
Pseudoephedrine |
Direct congestion positioning |
Does not treat histamine symptoms |
| Plain loratadine |
Loratadine |
None |
Broad OTC access and lower restrictions |
Does not provide systemic decongestion |
Claritin-D’s strongest commercial asset is brand familiarity. Its clinical differentiation is limited because comparable antihistamine-decongestant combinations are widely available.
What is the litigation and settlement outlook?
No ongoing, product-defining patent litigation or settlement structure is central to the current Claritin-D market. The litigation profile is more likely to involve:
- Trademark infringement.
- False advertising.
- Labeling and consumer-protection claims.
- Product liability.
- Manufacturing-quality disputes.
- Narrow formulation patents.
- Distribution and regulatory compliance.
There is no current settlement-based launch date that controls broad generic entry for the combination. Generic availability is established.
Key Takeaways
- Loratadine-pseudoephedrine sulfate is a mature OTC combination sold as Claritin-D and numerous generics.
- Core loratadine patent protection expired around the early 2000s.
- No current broad patent barrier prevents generic competition.
- The Orange Book and Paragraph IV mechanisms have limited commercial importance for the mature combination.
- Pseudoephedrine purchase controls are a larger operational constraint than patent rights.
- Bayer’s Claritin-D revenue is not separately disclosed.
- Financial performance depends on brand equity, seasonal allergy demand, retail distribution, and generic price pressure.
- The product has high generic substitution risk and modest remaining pricing power.
- Manufacturing quality, supply reliability, and retailer access are the primary barriers to entry.
- Biosimilar risk is not applicable because both active ingredients are small molecules.
FAQs
Is Claritin-D still patent protected?
The core loratadine and combination exclusivity has expired. Narrow formulation or manufacturing patents may exist, but they do not create a broad current barrier to generic competition.
Is loratadine-pseudoephedrine a generic drug?
Yes. Multiple generic and store-brand products contain loratadine and pseudoephedrine sulfate in 12-hour and 24-hour extended-release formats.
Does Claritin-D have separate FDA exclusivity?
No current market exclusivity materially protects Claritin-D from generic substitution. The product is commercially mature and operates in an OTC environment.
Why is pseudoephedrine kept behind the pharmacy counter?
Federal law restricts pseudoephedrine sales because the ingredient can be diverted for illicit methamphetamine production. Retailers must enforce purchase limits and maintain transaction records.
Is Claritin-D more valuable than plain loratadine?
The combination can command a higher retail price because it treats nasal congestion as well as allergy symptoms. Its economic value is limited by pseudoephedrine restrictions, side-effect concerns, and extensive generic competition.
References
-
U.S. Food and Drug Administration. (2002). FDA approves Claritin for over-the-counter use. FDA.
-
U.S. Drug Enforcement Administration. (n.d.). Combat methamphetamine epidemic act of 2005. U.S. Department of Justice.
-
Bayer AG. (2024). Annual report 2023. Bayer AG.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (n.d.). Drug facts and label information for OTC products. FDA.
